Oncology Pharma Inc. announced that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA tests for detecting cancer. In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England.